Viatris (VTRS) Exchange Rate Effect (2019 - 2026)
Viatris' (VTRS) quarterly Exchange Rate Effect came in at -$4.2 million in Q1 2026, down 125.0% year-on-year from $16.8 million in Q1 2025, and up 82.28% quarter-over-quarter from -$23.7 million in Q4 2025.
Viatris (VTRS) Exchange Rate Effect (2019 - 2026) Analysis & Trends
Viatris' Exchange Rate Effect history runs 8 years deep, the most recent figure standing at -$4.2 million for Q1 2026.
- On a quarterly basis, Exchange Rate Effect fell 125.0% year-over-year to -$4.2 million in Q1 2026; TTM through Mar 2026 was -$3.4 million, a 126.67% decrease from a year earlier, with the FY2025 full-year figure at $17.6 million, up 157.33% from the prior year.
- Exchange Rate Effect improved to -$4.2 million in Q1 2026 per VTRS's latest filing, from -$23.7 million in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $23.9 million in Q3 2024 and bottomed at -$37.8 million in Q4 2024.
- The 5-year median for Exchange Rate Effect is -$4.2 million (2026), against an average of -$3.5 million.
- Biggest YoY gain for Exchange Rate Effect was 1139.13% in 2024; the steepest drop was 1133.33% in 2024.
- Year by year, Exchange Rate Effect stood at $15.6 million in 2022, then retreated by 18.59% to $12.7 million in 2023, then plunged by 397.64% to -$37.8 million in 2024, then surged by 37.3% to -$23.7 million in 2025, then jumped by 82.28% to -$4.2 million in 2026.
- Per Business Quant, the three latest VTRS Exchange Rate Effect figures stand at -$4.2 million (Q1 2026), -$23.7 million (Q4 2025), and $17.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -17.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 17.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.01 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -4.20 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -5.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.20 Mn |
| Mar 31, 2026 | -4.20 Mn |
| Dec 31, 2025 | -23.70 Mn |
| Dec 31, 2025 | -23.70 Mn |
| Sep 30, 2025 | 17.80 Mn |
| Sep 30, 2025 | 17.80 Mn |
| Jun 30, 2025 | 6.70 Mn |
| Jun 30, 2025 | 6.70 Mn |
| Mar 31, 2025 | 16.80 Mn |
| Mar 31, 2025 | 16.80 Mn |
| Dec 31, 2024 | -37.80 Mn |
| Dec 31, 2024 | -37.80 Mn |
| Sep 30, 2024 | 23.90 Mn |
| Sep 30, 2024 | 23.90 Mn |
| Jun 30, 2024 | -4.40 Mn |
| Jun 30, 2024 | -4.40 Mn |
| Mar 31, 2024 | -12.40 Mn |
| Mar 31, 2024 | -12.40 Mn |
| Dec 31, 2023 | 12.70 Mn |
| Dec 31, 2023 | 12.70 Mn |